Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion

Non-small cell lung cancer (NSCLC) patients harboring MET exon 14 skipping or high MET amplification display a high rate of response to MET inhibitors. However, MET fusions in NSCLC have rarely been revealed. In this report, a 63-year-old woman with lung adenocarcinoma (LADC), harboring EGFR exon 18...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Lanzi, Tang, Yicong, Deng, Yanming, Guo, Lijie, He, Qingqing, He, Tingting, Feng, Weineng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360523/
https://www.ncbi.nlm.nih.gov/pubmed/35957915
http://dx.doi.org/10.3389/fonc.2022.911362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360523/
https://www.ncbi.nlm.nih.gov/pubmed/35957915
http://dx.doi.org/10.3389/fonc.2022.911362

Ejemplares similares